Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients

J. B. Konopka, S. Clark, J. McLaughlin, M. Nitta, Y. Kato, A. Strife, B. Clarkson, O. N. Witte

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

The consistent cytogenetic translocation of chronic myelogenous leukemia (the Philadelphia chromosome, Ph1) has been observed in cells of multiple hematopoietic lineages. This translocation creates a chimeric gene composed of breakpoint-cluster-region (bcr) sequences from chromosome 22 fused to a portion of the abl oncogene on chromosome 9. The resulting gene product (P210(c-abl)) resembles the transforming protein of the Abelson murine leukemia virus in its strucuture and tyrosine kinase activity. P210(c-abl) is expressed in Ph1 positive cell lines of myeloid lineage and in clinical specimens with myeloid predominance. We show here that Epstein-Barr virus-transformed B-lymphocyte lines that retain Ph1 can express P210(c-abl). The level of expression in these B-cell lines is generally lower and more variable than that observed for myeloid lines. Protein expression is not related to amplification of the abl gene but to variation in the level of bcr-abl mRNA produced from a single Ph1 template.

Original languageEnglish
Pages (from-to)4049-4052
Number of pages4
JournalProceedings of the National Academy of Sciences of the United States of America
Volume83
Issue number11
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Dive into the research topics of 'Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients'. Together they form a unique fingerprint.

Cite this